Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment? - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue European Journal of Dermatology Année : 2019

Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?

Résumé

Omalizumab is a recombinant humanized monoclonal antibody (mAb) targeting IgE, produced using Chinese hamster ovary (CHO) cell culture. It has been approved for the treatment of severe allergic asthma (SAA) and chronic urticaria but not for allergic rhinitis (AR), atopic dermatitis (AD) or food allergy, despite some benefits against these diseases [1]. Omalizumab treatment associated with allergen immunotherapy (AIT) can increase the tolerability of AIT [1]. Some anaphylactic reactions have been [...]
Fichier non déposé

Dates et versions

pasteur-03718435 , version 1 (08-07-2022)

Identifiants

Citer

Angelica Tiotiu, Claire Poreaux, Pascal Poncet, Hélène Senechal, J.L. Schmutz. Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?. European Journal of Dermatology, 2019, 29 (1), pp.101-2. ⟨10.1684/ejd.2018.3454⟩. ⟨pasteur-03718435⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More